RESUMEN
AIM: to evaluate the efficiency of decimeter wave therapy and halotherapy, which were additionally added to basic therapy, in patients with chronic obstructive pulmonary disease (COPD) concurrent with hypertension at the inpatient stage. SUBJECTS AND METHODS: 36 patients aged 20 to 75 years with Stages I-II COPD concurrent with Stages I-II, first-second grade hypertension were examined and treated. The clinical examination included collection of complaints and medical history data, clinical laboratory and instrumental (electrocardiography, spirography) studies, and health-related quality of life (using the SF-36 questionnaire). The patients were randomized into two groups: a study group and a comparison group. The study group patients received decimeter wave therapy and halotherapy in addition to basic drug treatment; the comparison patients had basic drug therapy. RESULTS: Pre- and postoperative comparative analysis of the major clinical manifestations of comorbidities revealed more pronounced positive changes with the lower rate of clinical manifestations in the study group. It was also observed to have a more marked reduction in blood pressure (BP) with its goal levels achieved. The mean pulse BP decreased by 28% in the study group (p=0.000005) and did not statistically reduced in the comparison group. In the study group patients, the integral quality-of-life indicator after a package of medical rehabilitation measures became statistically significantly higher by 35%. This indicator in the comparison group was statistically significantly unchanged. CONCLUSION: The directionality of the proposed rehabilitation complex towards the common pathogenetic components of the development and progression of COPD and hypertension, as well as the high efficiency of the complex justify its appropriate inclusion in the combination treatment and rehabilitation of this category of patients.
Asunto(s)
Hipertensión/epidemiología , Enfermedad Pulmonar Obstructiva Crónica , Calidad de Vida , Terapia Respiratoria/métodos , Terapia por Ondas Cortas/métodos , Cloruro de Sodio/administración & dosificación , Aerosoles/administración & dosificación , Capacidad Cardiovascular/fisiología , Capacidad Cardiovascular/psicología , Comorbilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Gravedad del Paciente , Modalidades de Fisioterapia , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/psicología , Enfermedad Pulmonar Obstructiva Crónica/rehabilitación , Pruebas de Función Respiratoria/métodos , Resultado del TratamientoAsunto(s)
Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Fragmentación del ADN , Intrones/genética , Activación Transcripcional/genética , Subunidad alfa 2 del Factor de Unión al Sitio Principal/deficiencia , Subunidad alfa 2 del Factor de Unión al Sitio Principal/metabolismo , Elementos de Facilitación Genéticos/genética , Silenciador del Gen , Células HEK293 , Histonas/genética , Histonas/metabolismo , Humanos , Células Jurkat , Matriz Nuclear/metabolismoRESUMEN
Transcription factor RUNX1 is one of the key regulatory proteins in vertebrates. It controls hematopoiesis and angiogenesis. It is indispensable during embryogenesis for the emergence of sites of definitive hematopoiesis and later in mature organisms for bone marrow blood stem cells differentiation. Moreover, RUNX1 gene is a frequent target for chromosomal translocations which cause acute forms of leukemia. A lot of types of human leukemia are somehow associated with mutations in this gene. Nevertheless, to this day the precise mechanism guiding the tissue-specific manner of the RUNX1 gene expression remains unknown. In this review we tried to summarize all the experimental data accumulated during the past twenty years beginning from the date when the cDNA sequence of the RUNX1 gene was first annotated. In the first part of the review we shall focus on structure, isoforms, covalent modifications of the RUNX1 transcription factor and its participation in different regulatory cascades. In the second part we shall discuss expression regulation, mutations and chromosomal translocations of the RUNX1 gene.
Asunto(s)
Subunidad alfa 2 del Factor de Unión al Sitio Principal , Regulación Leucémica de la Expresión Génica , Leucemia , Mutación , Proteínas de Neoplasias , Procesamiento Proteico-Postraduccional , Translocación Genética , Enfermedad Aguda , Animales , Subunidad alfa 2 del Factor de Unión al Sitio Principal/biosíntesis , Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Desarrollo Embrionario/fisiología , Hematopoyesis/fisiología , Humanos , Leucemia/genética , Leucemia/metabolismo , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , Neovascularización Fisiológica/fisiología , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/genéticaRESUMEN
Twenty patients of the control group without pathology of the thyroid gland were examined for development of the method of 3D-ultrasonic reconstruction and 3D-angiography. The study group consisted of 74 patients with nodular pathologies of the thyroid gland, 53 of them underwent surgery. Ultrasonic data was compared with results of clinical and laboratory studies, puncture biopsy and intraoperative data. Three-dimensional ultrasonic pictures permitted to detect spatial orientation of the nodes relative to lobes and segments of the thyroid gland, vascular structures, to evaluate character of nodes vascularization, to analyze nature and invasiveness of the tumor. Based on these data optimal variant of surgery was chosen. In 12 cases virtual modeling of surgeries with 3D-echography and ultrasonic angiography was performed. These methods permit to choose optimal variant of surgery and make possible prediction and prevention of complications.
